UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________________________________________________________
FORM 8-K
__________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
June 13, 2018
Date of Report
(Date of earliest event reported)
__________________________________________________________________________________________
Novus Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
__________________________________________________________________________________________
| ||||
|
|
|
|
|
Delaware (State or other jurisdiction of incorporation) |
| 001-36620 (Commission File Number) |
| 20-1000967 (IRS Employer Identification No.) |
19900 MacArthur Blvd., Suite 550
Irvine, California 92612
(Address of principal executive offices, including Zip Code)
(949) 238-8090
(Registrant’s telephone number, including area code)
__________________________________________________________________________________________
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☒
Novus Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders on June 13, 2018 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted in the following manner with respect to the following proposals:
1. | The election of two Class I directors, each to serve for a three-year term expiring at the 2021 annual meeting of stockholders and until his/her successor has been duly elected and qualified. |
|
|
|
|
|
| �� |
|
|
|
|
|
|
Nominees |
| For |
|
| Withheld |
|
| Broker Non-Votes |
| |||
Erez Chimovits |
|
| 2,563,826 |
|
|
| 147,799 |
|
|
| 2,950,332 |
|
Cheryl L. Cohen |
|
| 2,568,656 |
|
|
| 142,969 |
|
|
| 2,950,332 |
|
2. | The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. |
|
|
|
|
|
For: |
|
|
| 5,648,269 |
Against: |
|
|
| 3,624 |
Abstain: |
|
|
| 10,064 |
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
| |||
|
| ||
| Novus Therapeutics, Inc. |
| |
|
|
| |
|
|
| |
Date: June 14, 2018 | By:/s/ Gregory J. Flesher |
| |
| Name: Gregory J. Flesher |
| |
| Title: Chief Executive Officer |
| |
|
| ||
3